Use of polypharmacotherapy in pregnancy: a prospective outcome in a case


YARIS F. , Yaris E. , Kadioglu M., ULKU C., Kesim M., Kalyoncu N. İ.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, cilt.28, ss.603-605, 2004 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 28 Konu: 3
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.pnpbp.2004.01.010
  • Dergi Adı: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
  • Sayfa Sayıları: ss.603-605

Özet

Purpose: Little is known about the risks associated with prenatal exposure to atypical antipsychotics. Our objective is to present a case of exposure to risperidone and quetiapine in pregnancy, and additionally to some other drugs. Case: Our case (36-year old) has suffered schizophrenia (DSM-IV) for 5 years and used these drugs (risperidone, quetiapine, mirtazapine, thioridazine, diazepam, hydroxyzine, clomipramine, fluvoxamine, alprazolam, carbamazepine, biperiden, haloperidol, ampicillin + sulbactam, enoxaparin, oxerutine) in her third pregnancy. Because of her psychotic condition, Mrs. N.B. was not aware of her pregnancy until 22nd week and the pregnancy could not be terminated. She had a female infant (3000 g, 50 cm) with APGAR scores of 8-9 at the first and fifth minutes at 37th week with an uncomplicated vaginal delivery. The baby was normal. Conclusion: This case may contribute to the existing knowledge regarding use of atypical antipsychotics in pregnancy. (C) 2004 Elsevier Inc. All rights reserved.